WallStSmart

Anheuser Busch Inbev NV ADR (BUD)vsUniversal Health Services Inc (UHS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Anheuser Busch Inbev NV ADR generates 242% more annual revenue ($59.32B vs $17.36B). BUD leads profitability with a 11.5% profit margin vs 8.6%. UHS appears more attractively valued with a PEG of 1.29. UHS earns a higher WallStSmart Score of 76/100 (B+).

BUD

Buy

61

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 10.0Quality: 5.0

UHS

Strong Buy

76

out of 100

Grade: B+

Growth: 7.3Profit: 7.0Value: 10.0Quality: 7.5
Piotroski: 6/9Altman Z: 2.97
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BUDUndervalued (+51.3%)

Margin of Safety

+51.3%

Fair Value

$158.65

Current Price

$68.06

$90.59 discount

UndervaluedFair: $158.65Overvalued
UHSUndervalued (+78.6%)

Margin of Safety

+78.6%

Fair Value

$1081.08

Current Price

$186.72

$894.36 discount

UndervaluedFair: $1081.08Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BUD5 strengths · Avg: 8.6/10
EPS GrowthGrowth
63.3%10/10

Earnings expanding 63.3% YoY

Market CapQuality
$133.23B9/10

Large-cap with strong market position

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

Operating MarginProfitability
24.9%8/10

Strong operational efficiency at 24.9%

Free Cash FlowQuality
$9.89B8/10

Generating 9.9B in free cash flow

UHS4 strengths · Avg: 8.8/10
P/E RatioValuation
8.1x10/10

Attractively priced relative to earnings

Return on EquityProfitability
21.3%9/10

Every $100 of equity generates 21 in profit

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

EPS GrowthGrowth
42.7%8/10

Earnings expanding 42.7% YoY

Areas to Watch

BUD2 concerns · Avg: 4.0/10
PEG RatioValuation
1.604/10

Expensive relative to growth rate

Revenue GrowthGrowth
4.8%4/10

4.8% revenue growth

UHS0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : BUD

The strongest argument for BUD centers on EPS Growth, Market Cap, Price/Book.

Bull Case : UHS

The strongest argument for UHS centers on P/E Ratio, Return on Equity, Price/Book. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bear Case : BUD

The primary concerns for BUD are PEG Ratio, Revenue Growth.

Bear Case : UHS

No major red flags identified for UHS, but monitor valuation.

Key Dynamics to Monitor

UHS carries more volatility with a beta of 1.26 — expect wider price swings.

UHS is growing revenue faster at 9.1% — sustainability is the question.

BUD generates stronger free cash flow (9.9B), providing more financial flexibility.

Monitor BEVERAGES - BREWERS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

UHS scores higher overall (76/100 vs 61/100). BUD offers better value entry with a 51.3% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Anheuser Busch Inbev NV ADR

CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA

Anheuser-Busch InBev SA / NV is engaged in the production, distribution and sale of beer, alcoholic beverages and soft drinks worldwide.

Universal Health Services Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

UnitedHealth Group Incorporated is an American for-profit multinational managed healthcare and insurance company based in Minnetonka, Minnesota. It offers health care products and insurance services.

Visit Website →

Want to dig deeper into these stocks?